Microwaves are a common appliance in every household now. You will see it in kitchens of not just houses, but offices, cafeterias, and co working space. However, there are studies that show that heating food in a microwave could be a health concern. While it does come handy, there are questions about harmful radiation and nutrient loss and heating safety that still linger.
Some research suggests that microwaving may cause nutritional loss, particularly in vegetables. For example, studies have shown that microwaving broccoli with water diminishes its flavonoid content, which are anti-inflammatory compounds. However, experts note that cooking method and duration have a significant influence on nutrient retention.
Surprisingly, several studies indicate that microwaving preserves more nutrients than traditional cooking methods. A study comparing microwaved versus oven-cooked ready meals found that the microwaved version contained somewhat more vitamin C. Another study discovered that microwaving some vegetables, such as broccoli and green beans, may retain more beneficial compounds than boiling.
Ultimately, the nutrient loss really vary on the type of food which is being heated and how it is being cooked. Experts also recommend using minimal water and shorter cooking times to maximize the nutrient retention.
Plastic containers and heating food in it, has always been a topic of debate. While containers do come with microwave-safe stamps, is it really safe to heat them with food?
According to research, when certain plastics are subjected to heat, they produce compounds such as phthalates and bisphenol A (BPA). These substances have been associated to hormonal disturbance, metabolic problems, and perhaps reproductive concerns.
A study also took in account over 400 plastic food containers that were microwave-safe and found that most of them leaked hormone-disrupting chemicals. These are phthalates, warn experts, which are commonly used in food packaging and can interfere with body's hormonal balance, and increase risk of diabetes or even high blood pressure.
Additionally, BPA exposure has been associated with fertility issues and immune system disruptions.
To minimize this risk, experts recommend using glass or ceramic container when microwaving foods. If you must use a plastic container, make sure the container is not damaged or old, as they are more prone to leach harmful chemicals.
Concerns about microwave radiation have been largely debunked by decades of research. Microwaves use non-ionizing radiation, which does not have enough energy to damage DNA or cause cancer. The electromagnetic waves used in microwaves are similar to those from radios and light bulbs.
Experts emphasize that microwave ovens are designed to contain radiation, preventing exposure. As long as the microwave is in good condition and the door seals properly, there is no significant health risk from microwave radiation.
Microwaving food could sometimes also lead to uneven cooking and it can create some risks to food safety. Thus, experts advertise to use microwave only to reheat the food and not to actually cook raw food. For safe reheating, food should reach at least 82°C (176°F) throughout to kill bacteria.
Credit: iStock
While research shows women need more sleep than men due to brain function, hormones, and multitasking, females around the globe are struggling to get enough sleep, according to experts.
A 2016 study by the Sleep Research Centre at the UK’s Loughborough University found that women needed 20 minutes more sleep because of multitasking and performing more complex brain tasks during the day.
But, the American Academy of Sleep Medicine (AASM), revealed that an estimated 30 percent of women fail to get sufficient sleep.
Hormones, mood disorders, and caregiving responsibilities, coupled with professional pressures and stress, are the major reasons driving up insomnia and other sleep issues among women.
“Women around the world face a higher burden of sleep difficulties because their sleep cycles are tightly interlinked with hormonal shifts that occur throughout life,” Dr. Janhvi Siroya Shah, Sleep Specialist from the University of Bern, Switzerland, told HealthandMe.
The gender gap in sleep is real, as revealed by the recent ResMed Global Sleep Survey 2026, which showed that 56 percent of women get a good night's sleep only four days or fewer per week, compared to 50 percent of men.
Women were also 48 percent more likely to report problems falling asleep than men (42 percent). More than 50 percent of women felt waking up not feeling rested for 1-2 nights per week or more, compared to 46 percent of men.
The study flagged stress or anxiety as the biggest barrier to consistent, quality sleep (39 per cent), followed by work-related responsibilities (37 per cent) and household duties (31 per cent) among women.
Speaking to HealthandMe, Dr. Kirti Kadian, from the Department of Pulmonary Critical Care & Sleep Medicine at AIIMS Bhopal, said: “Women experience disproportionate sleep challenges globally, largely because their bodies undergo repeated physiological transitions that influence how sleep is regulated.”
The experts cited the main reasons as
All these factors can alter mood regulation, increase nighttime alertness, and disrupt the architecture of sleep itself.
Dr Kadian said that hormonal fluctuations across the life course -- especially during the menopausal transition -- can affect circadian rhythm, airway stability, pain sensitivity, and the nervous system’s response to stress.
“When these biological changes coincide with external stressors, such as multitasking, emotional labor or caregiving demands, women become far more vulnerable to insomnia and unrefreshing sleep,” Shah said.
The prevalence of sleep disorders increases from about 16–42 percent in pre-menopause to around 39–47 percent in peri-menopause and up to 35–69 percent in post-menopause, indicating that sleep disturbances become more common as women progress through different reproductive stages.
“Declining levels of estrogen and progesterone can disrupt the body’s sleep regulation and trigger symptoms like hot flashes and night sweats, while reduced melatonin may make it harder to fall and stay asleep,” Dr. Kadian explained.
In addition, certain medical conditions that are more common in women, such as thyroid disorders, anemia, and autoimmune diseases, can also negatively affect sleep and overall health.
Poor sleep also significantly affects both physical and mental health, increasing the risk of
The Harvard Medical School suggested that to get a better sleep cycle women should:
Credit: iStock
While early-stage research raised hopes of oral semaglutide (GLP-1 pill) slowing down the progression of Alzheimer’s disease, results of a new large-scale clinical trial have rendered it ineffective.
Evoke and Evoke+ -- the randomized, double-blind, placebo-controlled phase 3 trials conducted across 566 sites in 40 countries -- showed that semaglutide led to no significant difference after two years.
The findings, published in the Lancet journal, however, revealed that the popular weight loss drug can lead to significant reductions in several biological markers of Alzheimer’s disease.
Yet, it did not help slow the progression of the neurodegenerative disease, said an international team of researchers, including those from the University of California-San Diego.
"Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer's disease," they said in the paper.
"Safety and tolerability of semaglutide in early Alzheimer's disease is consistent with studies in other indications," the team added.
The studies are the first major phase 3 trials to investigate this possibility in people with early Alzheimer’s disease.
The researchers conducted the trial on about 3,800 patients aged 55-85 years. The patients received either up to 14 mg of oral semaglutide daily or a placebo pill.
After two years, no significant difference was seen in slowing down the cognitive disease's progression in patients taking semaglutide and patients taking the placebo.
"The results of the large evoke(+) trials do not support the efficacy of 14 mg/day of semaglutide given for up to 156 weeks in participants with biomarker-confirmed Alzheimer's disease in the MCI or mild dementia stage," the researchers said.
While “GLP-1 [drugs] have given us so many wonderful results," the trial results are "disappointing,” and “a setback for the field”, endocrinologist Daniel Drucker was quoted as saying to the Scientific American.
Drucker says there are many potential explanations why oral semaglutide didn’t work as hoped. The fatty-acid structure surrounding semaglutide might have prevented it from being able to penetrate certain brain regions, such as the hippocampus, which controls memory and cognitive function.
Alzheimer's disease is a progressive neurodegenerative disease characterised by gradual cognitive and functional decline.
It is one of the most common forms of dementia and mostly affects adults over the age of 65.
Over seven million people in the US, 65 and older, live with the condition, and over 100,00 die from it annually.
The disease is believed to be caused by the development of toxic amyloid and beta proteins in the brain, which can accumulate and damage cells responsible for memory.
Early symptoms of Alzheimer's disease include forgetting recent events or conversations. Other signs include:
Credit: iStock
In the year 1947, on the remote Scottish island of Jura, George Orwell sat hunched over a typewriter in a farmhouse, engaged in a desperate race against time to finish his masterpiece, 1984, while a ‘slow-motion plague’ consumed his lungs.
The man who was born in Motihari, Bihar, was suffering from tuberculosis. He would cough up blood and frequently collapse out of sheer exhaustion, even as he typed the final warnings of a dystopian future. He finished the book in December 1948 and died just over a year later.
Orwell’s story is a haunting reminder that TB has always been a disease of the displaced. As we approach World Tuberculosis Day this year with the theme ‘Yes! We Can End TB: Led by countries, powered by people, we face a sobering reality.
We have the modern tools that Orwell lacked, but the global narrative remains trapped in an outdated cycle where technological potential far outstrips operational reality. To end this disease, we must stop viewing TB through a narrow clinical lens and start addressing the systemic inefficiencies that leave out millions.
For decades, a diagnosis of drug-resistant TB (DR-TB) was a near-death sentence even with treatment. Patients faced a grueling 18 to 24-month treatment regimen involving thousands of pills and daily painful injections that often caused permanent side effects like deafness.
With the introduction of the BPaLM regimen (Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin), this tide seems to have turned. The all-oral four-drug treatment, touted as a medical miracle, has slashed recovery time for drug-resistant strains to just six months.
However, even a magic pill cannot overcome a broken system. We must distinguish between clinical success and social success. A patient might technically be cured of the bacteria, but if they lose their job or suffer from social stigma during those six months, the system has still failed them.
Statistically, men bear a higher burden of TB, yet they are often the hardest to bring into the care net. According to the World Health Organization (WHO), men account for approximately 55 per cent of all TB cases globally, compared to 33 per cent for women and 12 per cent for children.
This is not a biological accident; it is a structural failure. Gendered social norms often prevent men from seeking care until the disease is advanced. As primary earners, the prospect of losing wages – combined with the stigma of diagnosis – creates a powerful disincentive to visit a clinic. To be truly people-centered, we must move away from static clinic hours and towards flexible, community-based care that reaches men at places where they work.
Treating TB in isolation is an outdated strategy. We see patients suffering from a double burden because TB is usually accompanied by diabetes, malnutrition, or even HIV.
Despite this, our medical systems remain stubbornly reserved. A patient is often forced to navigate fragmented clinics that rarely communicate. Integration is the only way to ensure we treat the whole person, not just the pathogen.
The path forward requires us to acknowledge that we cannot end TB by looking only at the lungs; we must look at the lives of those affected. The end of TB is a matter of leadership and courage to fix the systems that hold medical science back.
As we look towards World Tuberculosis Day, let us not just renew our commitments; let us hold our systems to account. The human cost of cure is currently too high, not because of the medicine, but because of the world in which the medicine is delivered.
As we honor World Tuberculosis Day, let us ensure that no one else has to choose between finishing their life’s work and surviving a curable disease. Curing tuberculosis is no longer a biological mystery; it is a test of our collective humanity.
© 2024 Bennett, Coleman & Company Limited